A Preliminary Report on the Prognostic Significance of Preoperative Brain Natriuretic Peptide and Postoperative Cardiac Troponin in Patients Undergoing Major Vascular Surgery

被引:36
作者
Bolliger, Daniel [1 ]
Seeberger, Manfred D. [1 ]
Buse, Giovanna A. L. Lurati [1 ]
Christen, Peter [2 ]
Rupinski, Brian. [1 ]
Guerke, Lorenz [3 ]
Filipovic, Miodrag [1 ]
机构
[1] Univ Basel Hosp, Dept Anesthesia, CH-4031 Basel, Switzerland
[2] Cantonal Hosp Lucerne, Dept Anesthesia, Luzern, Switzerland
[3] Univ Basel Hosp, Div Vasc Surg, CH-4031 Basel, Switzerland
关键词
PERIOPERATIVE CARDIOVASCULAR EVALUATION; NONCARDIAC SURGERY; RISK; MORTALITY; ASSOCIATION; PREDICTION; UTILITY; EVENTS; MARKER; BNP;
D O I
10.1213/ane.0b013e318194f3e6
中图分类号
R614 [麻醉学];
学科分类号
100217 ;
摘要
BACKGROUND: Associations between preoperative elevation of brain natriuretic peptide (BNP) or postoperative elevation of cardiac troponins (cTn) with major adverse cardiac events (MACE) after major surgery have been shown previously. In this study, we evaluated the added value of preoperative BNP with postoperative cTn levels for the prediction of MACE in patients undergoing major vascular surgery. METHODS: This is a prospectively prespecified, secondary analysis of data from a cohort of 133 clinically stable patients undergoing major vascular surgery enrolled in a clinical trial evaluating the effectiveness of the sympathetic nervous system-inhibiting drug moxonidine on reducing MACE. Concentrations of BNP and cTn were determined before surgery, and concentrations of cTn were measured immediately after surgery and on postoperative days 1, 2, 3, and 7. The primary end point was the occurrence of MACE (defined as any hospitalization for myocardial revascularization, acute coronary syndrome, acute congestive heart failure, or death by any cause) within 1 yr after surgery. Patients were evaluated for MACE by hospital chart review during hospitalization and by telephone interviews 12 mo after surgery. RESULTS: Within 7 yr after surgery, 1.9 patients (14%) had a MACE, including 14 patients (11%) who died. After adjustment for age, gender, and the revised cardiac risk index preoperative BNP elevation >= 50 pg/mL was associated with MACE (adjusted hazard ratio [HR]: 6.5, 95% confidence interval [CI]: 1.4-29.5) regardless of the subsequent cTn I concentrations. The combination of preoperative BNP elevation >= 50 pg/mL and postoperative cTn I elevation >= 2 ng/mL was associated with MACE (adjusted HR: 25.2, 95% CI: 5.0-128.4) and all-cause mortality (adjusted HR: 18.7, 95% CI: 3.1-112.5). The negative predictive value of a normal preoperative BNP value for subsequent adverse events was 0.965 (95% CI: 0.879-0.996). CONCLUSION: These data suggest that measurement of preoperative BNP concentrations in addition to postoperative cTn concentrations provides additive prognostic information for MACE and mortality after major vascular surgery.
引用
收藏
页码:1069 / 1075
页数:7
相关论文
共 25 条
[1]  
Apple Fred S, 2007, Circulation, V115, pe352
[2]   Randomized clinical trial of moxonidine in patients undergoing major vascular surgery [J].
Bolliger, D. ;
Seeberger, M. D. ;
Buse, G. A. L. Lurati ;
Christen, P. ;
Guerke, L. ;
Filipovic, M. .
BRITISH JOURNAL OF SURGERY, 2007, 94 (12) :1477-1484
[3]   Utility of B-type natriuretic peptide in predicting perioperative cardiac events in patients undergoing major non-cardiac surgery [J].
Cuthbertson, B. H. ;
Almiri, A. R. ;
Croal, B. L. ;
Rajagopalan, S. ;
Alozairi, O. ;
Brittenden, J. ;
Hillis, G. S. .
BRITISH JOURNAL OF ANAESTHESIA, 2007, 99 (02) :170-176
[4]   Utility of B-type natriuretic peptide in predicting medium-term. mortality in patients undergoing major non-cardiac surgery [J].
Cuthbertson, Brian H. ;
Amiri, Amir R. ;
Croal, Bernard L. ;
Rajagopalan, Sriram ;
Brittenden, Julie ;
Hillis, Graham S. .
AMERICAN JOURNAL OF CARDIOLOGY, 2007, 100 (08) :1310-1313
[5]   Natriureettic peptides [J].
Daniels, Lori B. ;
Maisel, Alan S. .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2007, 50 (25) :2357-2368
[6]   B-type natriuretic peptide in cardiovascular disease [J].
de Lemos, JA ;
McGuire, DK ;
Drazner, MH .
LANCET, 2003, 362 (9380) :316-322
[7]   Assessment of cardiac risk before non-cardiac surgery: brain natriuretic peptide in 1590 patients [J].
Dernellis, J. ;
Panaretou, M. .
HEART, 2006, 92 (11) :1645-1650
[8]   Surveillance and prevention of major perioperative ischemic cardiac events in patients undergoing noncardiac surgery: a review [J].
Devereaux, PJ ;
Goldman, L ;
Yusuf, S ;
Gilbert, K ;
Leslie, K ;
Guyatt, GH .
CANADIAN MEDICAL ASSOCIATION JOURNAL, 2005, 173 (07) :779-788
[9]   ACC/AHA guideline update for perioperative cardiovascular evaluation for noncardiac surgery - Executive summary [J].
Eagle, KA ;
Berger, PB ;
Calkins, H ;
Chaitman, BR ;
Ewy, GA ;
Fleischmann, KE ;
Fleisher, LA ;
Froehlich, JB ;
Gusberg, RJ ;
Leppo, JA ;
Ryan, T ;
Schlant, RC ;
Winters, WL ;
Gibbons, RJ ;
Antman, EM ;
Alpert, JS ;
Faxon, DP ;
Fuster, V ;
Gregoratos, G ;
Jacobs, AK ;
Hiratzka, LF ;
Russell, RO ;
Smith, SC .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2002, 39 (03) :542-553
[10]   Plasma N-terminal pro-B-type natriuretic peptide as long-term prognostic marker after major vascular surgery [J].
Feringa, Harm H. H. ;
Schouten, Olaf ;
Dunkelgrun, Martin ;
Bax, Jeroen J. ;
Boersma, Eric ;
Elhendy, Abdou ;
de Jonge, Robert ;
Karagiannis, Stefanos E. ;
Vidakovic, Radosav ;
Poldermans, Don .
HEART, 2007, 93 (02) :226-231